A case of ANCA-associated vasculitis in a 16-year-old female following SARS-COV-2 infection and a systematic review of the literature

Table 1 Pulmonary function tests before and after AAV treatment

Pulmonary function tests prior to treatment			Pulmonary function tests after treatment
		% Predicted		% Predicted
FVC (L)	2.62	75	3.88	96
FEV1 (L)	1.95	63	3.04	86
FEV1/FVC (%)	74.6	85	68.0	78
FEF 25–75% (L/Second)	1.82	1.82	2.80	68
PEF (L/Second)	2.27	30	5.15	73

FEV1 Forced expiratory volume in one second, FVC, Forced vital capacity FEV1/FVC ratio, Percentage of the FVC expired in one second FEF 25–75%, Forced expiratory flow over the middle one-half of the FVC PEF, Peak expiratory flow

ISSN: 1546-0096